CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
N Engl J Med. 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768.
N Engl J Med. 2022.
PMID: 35476655
No abstract available.